

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 125413		APPLICATION NO. 10/549,510	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANTS Yukinori MASUDA et al.			
				FILING DATE September 20, 2005		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
CA	1.	4,885,284	12/05/1989	Kiyotomo SETO et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
CA	2.	JP-A-61-030591 w/ abst.	02/12/1986	JAPAN			
CA	3.	JP-A-60-069089 w/ abst.	04/19/1985	JAPAN			
CA	4.	JP-A-01-275591 w/ abst.	11/06/1989	JAPAN			
CA	5.	JP-A-61-063688 w/ abst.	04/01/1986	JAPAN			
CA	6.	JP-A-63-233992 w/ abst.	09/29/1988	JAPAN			
CA	7.	JP-A-62-169795 w/ abst.	07/25/1987	JAPAN			
CA	8.	JP-A-62-169796 w/ abst.	07/25/1987	JAPAN			
CA	9.	EP 0 500 426 A1	08/26/1992	EUROPEAN PATENT OFFICE			
CA	10.	WO 01/04124 A1	01/18/2001	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
CA	11.	Haruko MASUMIYA et al.; "Effects of Ca <sup>2+</sup> channel antagonists on sinus node: Prolongation of late phase 4 depolarization by efonidipine"; <i>European Journal of Pharmacology</i> ; Vol. 335; 1997; pp. 15-21.					
CA	12.	Paul MULDER et al.; "Increased Survival After Long-Term Treatment with Mibefradil, a Selective T-Channel Calcium Antagonist, in Heart Failure"; <i>JACC</i> ; Vol. 29, No. 2; February 1997; pp. 416-421.					
CA	13.	Johanne VILLAME et al.; "Effects of Mibefradil, a T- and L-Type Calcium Channel Blocker, on Cardiac Remodeling in the UM-X7.1 Cardiomyopathic Hamster"; <i>Cardiovascular Drugs and Therapy</i> ; Vol. 15; 2001; pp. 41-48.					
CA	14.	Samir FAREH et al.; "The T-Type Ca <sup>2+</sup> Channel Blocker Mibefradil Prevents the Development of a Substrate for Atrial Fibrillation by Tachycardia-Induced Atrial Remodeling in Dogs"; <i>Circulation</i> ; Vol. 100; November 23, 1999; pp. 2191-2197.					
EXAMINER				DATE CONSIDERED			
AWLAKH				11/18/08			
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 125413		APPLICATION NO. 10/549,510	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANTS Yukinori MASUDA et al.			
				FILING DATE September 20, 2005		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
CA	15.	Georg NOLL et al.; "Comparative Pharmacological Properties among Calcium Channel Blockers: T-Channel versus L-Channel Blockade"; <i>Cardiology</i> ; Vol. 89; Supp. 1; 1998; pp. 10-15.					
CA	16.	Chris BAYLIS et al.; "Comparison of L-Type and Mixed L- and T-Type Calcium Channel Blockers on Kidney Injury Caused by Deoxycorticosterone-Salt Hypertension in Rats"; <i>American Journal of Kidney Diseases</i> ; Vol. 38, No. 6; 2001; pp. 1292-1297.					
CA	17.	D. BILICI et al.; "Protective Effect of T-Type Calcium Channel Blocker in Histamine-Induced Paw Inflammation in Rat"; <i>Pharmacological Research</i> ; Vol. 44, No. 6; 2001; pp. 527-531.					
CA	18.	Sebastien LENGLET et al.; "Activation of 5-HT <sub>7</sub> Receptor in Rat Glomerulosa Cells is Associated with an Increase in Adenylyl Cyclase Activity and Calcium Influx through T-Type Calcium Channels"; <i>Endocrinology</i> ; Vol. 143, No. 5; pp. 1748-1760.					
CA	19.	J. Bruce MCCALLUM et al.; "Loss of T-type Calcium Current in Sensory Neurons of Rats with Neuropathic Pain"; <i>Anesthesiology</i> ; Vol. 98, No. 1; 2003; pp. 209-216.					
CA	20.	Darrell M. PORCELLO et al.; "Actions of U-92032, a T-Type CA <sup>2+</sup> Channel Antagonist, Support a Functional Linkage Between I <sub>T</sub> and Slow Intrathalamic Rhythms"; <i>Journal of Neurophysiology</i> ; Vol. 89; January 2003; pp. 177-185.					
EXAMINER				DATE CONSIDERED			
AWLAKH				1/18/08			
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: December 20, 2005